A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

计划入组 114 人 · 首次发布于 2019 年 12 月 23 日

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

计划入组 20 人 · 首次发布于 2015 年 10 月 19 日

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

计划入组 40 人 · 首次发布于 2017 年 8 月 22 日

VS-014

VS-501

VS-02

HilleVax

United States

Renovion, Inc.

United States

Dyve Biosciences, Inc.

United States

Vasa Therapeutics Partners with Lilly TuneLab to Accelerate AI-Driven CAMKII Inhibitor Development

Pelabresib Plus Ruxolitinib Shows Significant Benefit in Myelofibrosis Patients

AdAlta Completes Global Patent Protection for Anti-Fibrotic Drug AD-214 with Canadian Approval